Global COVID-19 – Pipeline Analysis 2020
- UNI4065917
- 164 Pages
- April 2020
- Healthcare
COVID-19 is mainly transmitted through contact with respiratory droplets rather than through the air and spreads primarily through contact with an infected person when they cough or sneeze. It also spreads when a person touches a surface or object that has the virus on it, then touches their eyes, nose, or mouth. A patient might take 1 to 14 days before developing symptoms as corona virus has an incubation period of 14 days. The most common symptoms of COVID-19 include dry cough, tiredness, fever and difficulty breathing (severe cases). Some patients may also suffer from aches and pains, runny nose, nasal congestion, sore throat or diarrhoea.
The diagnosis of the disease can be done by several methods such as nucleic acid test, serologic diagnosis and imaging technology. Chest radiograph or CT is an important tool for COVID-19 diagnosis in clinical practice. The majority of Covide-19 cases have similar features on CT images. Currently no antiviral treatment available for SARS-CoV-2 however, companies and research institutes are working towards it. Therapeutic agents targeting nucleosides, nucleotides, viral nucleic acids and enzymes/proteins involved in the replication and transcription of coronaviruses can be promising strategies to treat coronavirus diseases.
The pipeline of COVID-19 consists of approximately 85+ products in different stages of development. It includes therapeutic drugs and vaccines. Currently, 8+ drugs are in Phase III development and major drugs are in pre-clinical stage. Moreover, 42 vaccines are under development by various companies, and 2+ vaccines are in Phase I trial.
Top Company Analysed
Some of the key players include in the analysis includes Ascletis Pharma Inc., OncoImmune, FUJIFILM Toyama Chemical Co., Ltd.; Sanofi, Gilead Sciences, Incyte Corporation, Hoffmann La Roche, Vanda Pharmaceuticals, Apeiron Biologics and Relief Therapeutics Holdings among others.
The report provides an overview of therapeutic pipeline activity for COVID-19 across the complete product development cycle including all clinical and non-clinical stages
The report comprises of detailed profiles of COVID-19 therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, technologies and chemical information
Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
Detailed profiles of the clinical vaccines and listing of the non-clinical vaccines under development by companies
Listing of the vaccines under development by universities
Reasons to buy:
The COVID-19 pipeline report presents the detailed profile of drugs. The analysis offered in the report is a combination of deep dive secondary research and input from Key Opinion Leader of the industry
The report presents a quick review of the current scenario regarding the drug development of the indication at one glance
The report covers in-depth analysis of prominent industry peers with a primary focus on company consolidation, technology, agreements and patents regarding the therapy
Detailed examination on diagnosis and treatment prevailing in the industry
The study comprehensively covers the market across drugs in different phases of development
Customization Options:
The COVID-19 Pipeline analysis report can be customized to the country level or any other competitive segment. Besides this, UMI understands that you may have your own business need, hence we also provide fully customized solutions to clients.
1.1 Objective of the Study 12
1.2 Limitation 12
1.3 Stakeholders 12
1.4 Currency used in the Report 12
1.5 Secondary Research 12
1.6 Scope of the COVID-19 – Pipeline Analysis Study 12
2. RESEARCH METHODOLOGY OR ASSUMPTION 14
2.1 Research Methodology for the COVID-19 – Pipeline Analysis 2020 14
2.1.1 Main objective of the COVID-19 – Pipeline Analysis 2020 14
3. EXECUTIVE SUMMARY 16
4. DISEASE OVERVIEW 18
4.1 Introduction 18
4.2 Etiology 19
4.3 Virology 19
4.3.1 Physicochemical Properties 21
4.3.2 Receptor Interactions and Cell Entry 21
4.4 Diversity of Coronaviruses 22
4.5 Epidemiology and clinical features of human coronaviruses 22
4.5.1 Source of Infection 22
4.5.2 Spectrum of Infection 22
4.5.3 Clinical Features 23
4.5.4 Epidemiological Characteristics in Mainland China and other countries 24
4.5.5 Herd Susceptibility 25
4.6 Pathogenesis 25
4.6.1 Virus Entry and Spread 25
4.6.2 Pathological Findings 26
4.6.3 Acute Respiratory Distress Syndrome (ARDS) 26
4.6.4 Cytokine Storm 26
4.6.5 Immune Dysfunction 27
4.7 Signs and Symptoms 29
4.8 Diagnostic testing 31
4.8.1 Nucleic Acid Test 48
4.8.2 Serologic Diagnosis 49
4.8.3 CRISPR/Cas13 System 49
4.8.4 Imaging Technology 49
4.9 Treatment 50
4.9.1 Type I IFNs 50
4.9.2 Convalescent Plasma 53
4.9.3 Protective Monoclonal Antibody 53
4.9.4 Protease 53
4.9.5 Others 54
4.9.6 Vaccines 54
4.9.7 Proposed COVID-19 Triage Algorithm for Low-income Settings Without Established Local Transmission 56
5. PIPELINE THERAPEUTICS AT A GLANCE 57
5.1 General Overview (Clinical Stage Products) 57
5.2 General Overview (Non-Clinical Stage Products 58
6. CLINICAL PRODUCTS UNDER DEVELOPMENT BY TARGET 59
7. COMPARATIVE ANALYSIS 61
7.1 General Overview 61
8. LATE PHASE PRODUCTS (PHASE III) 62
8.1 Comparative Analysis 62
8.2 ASC09+Ritonavir: Ascletis Pharmaceuticals Co., Ltd. 63
8.2.1 Product Description 63
8.2.2 Research and Development 63
8.2.2.1 Clinical Studies 63
8.2.2.1.1 Phase III 63
8.2.3 Product Development Activities 64
8.2.3.1 Collaboration 64
8.3 CD24Fc: OncoImmune 66
8.3.1 Product Description 66
8.3.2 Research and Development 67
8.3.2.1 Clinical Studies 67
8.3.2.1.1 Phase III 67
8.4 Favipiravir: FUJIFILM Toyama Chemical Co., Ltd. 69
8.4.1 Product Description 69
8.4.2 Research and Development 70
8.4.2.1 Clinical Studies 70
8.4.2.1.1 Phase III 70
8.5 Hydroxychloroquine: Sanofi-Aventis 72
8.5.1 Product Description 72
8.5.2 Research and Development 72
8.5.2.1 Clinical Studies 72
8.5.2.1.1 Phase III 72
8.6 Remdesivir: Gilead Sciences 76
8.6.1 Product Description 76
8.6.2 Research and Development 76
8.6.2.1 Pre-clinical Studies 76
8.6.2.2 Clinical Studies 77
8.6.2.2.1 Phase III 77
8.7 Ruxolitinib: Incyte Corporation 79
8.7.1 Product Description 79
8.7.2 Research and Development 79
8.7.2.1 Clinical Studies 79
8.7.2.1.1 Phase III 79
8.7.3 Product Development Activities 80
8.7.3.1 Collaboration Agreement 80
8.8 Tocilizumab: Hoffmann-La Roche 82
8.8.1 Product Description 82
8.8.2 Research and Development 83
8.8.2.1 Clinical Studies 83
8.8.2.1.1 Phase III 83
8.9 Tradipitant: Vanda Pharmaceuticals 85
8.9.1 Product Description 85
8.9.2 Research and Development 86
8.9.2.1 Clinical Studies 86
8.9.2.1.1 Phase III 86
8.9.3 Product Development Activities 86
8.9.3.1 Licensing Agreement 86
8.9.3.2 Patent 86
9. MID PHASE PRODUCTS (PHASE II) 88
9.1 Comparative Analysis 88
9.2 APN-01: Apeiron Biologics 89
9.2.1 Product Description 89
9.2.2 Research and Development 90
9.2.2.1 Clinical Studies 90
9.2.2.1.1 Phase II 90
9.2.3 Product Development Activities 90
9.2.3.1 Acquisition Agreement 90
9.3 Aviptadil: Relief Therapeutics 92
9.3.1 Product Description 92
9.3.2 Research and Development 92
9.3.2.1 Clinical Studies 92
9.3.2.1.1 Phase II 92
9.3.3 Product Development Activities 92
9.3.3.1 Divestment Agreement 92
9.3.3.2 IND Application 93
9.3.3.3 Acquisition Agreement 93
9.4 BXT-10: Bioxytran 95
9.4.1 Product Description 95
9.4.2 Research and Development 96
9.4.2.1 Pre-clinical Studies 96
9.4.2.2 Clinical Studies 96
9.4.2.2.1 Phase II 96
9.4.3 Product Development Activities 97
9.4.3.1 Licensing 97
9.5 Leronlimab: CytoDyn 98
9.5.1 Product Description 98
9.5.2 Research and Development 98
9.5.2.1 Clinical Studies 98
9.5.2.1.1 Phase II 98
9.5.3 Product Development Activities 99
9.5.3.1 Acquisition Agreement 99
9.6 Lopinavir+Ritonavir: AbbVie 101
9.6.1 Product Description 101
9.6.2 Research and Development 101
9.6.2.1 Clinical Studies 101
9.6.2.1.1 Phase II 101
9.6.3 Product Development Activities 101
9.6.3.1 Collaboration 101
9.7 Plitidepsin: PharmaMar 103
9.7.1 Product Description 103
9.7.2 Research and Development 103
9.7.2.1 Preclinical Studies 103
9.7.2.2 Clinical Studies 104
9.7.2.2.1 Phase II 104
9.8 Sarilumab: Sanofi-Aventis 106
9.8.1 Product Description 106
9.8.2 Research and Development 107
9.8.2.1 Clinical Studies 107
9.8.2.1.1 Phase II/III 107
9.8.3 Product Development Activities 108
9.8.3.1 Collaboration Agreement 108
9.8.3.2 Technology 109
9.9 SNG001: Synairgen Research 111
9.9.1 Product Description 111
9.9.2 Research and Development 111
9.9.2.1 Clinical Studies 111
9.9.2.1.1 Phase II 111
9.9.3 Product Development Activities 112
9.9.3.1 Technology 112
10. EARLY STAGE PRODUCTS (PHASE I and IND) 115
10.1 Comparative Analysis 115
10.2 AmnioBoost: Lattice Biologics 116
10.2.1 Product Description 116
10.2.2 Research and Development 116
10.2.2.1 Clinical Studies 116
10.2.2.1.1 Phase I 116
10.3 Baloxavir marboxil/Favipiravir and Lopinavir/Ritonavir: Shionogi & Co., Ltd. 118
10.3.1 Product Description 118
10.3.2 Research and Development 118
10.3.2.1 Clinical Studies 118
10.3.2.1.1 Phase 0 118
10.4 Gimsilumab: Roivant Sciences 120
10.4.1 Product Description 120
10.4.2 Research and Development 120
10.4.2.1 Clinical Studies 120
10.4.2.1.1 Phase I 120
10.5 REGN3048+REGN3051: Regeneron Pharmaceuticals 122
10.5.1 Product Description 122
10.5.2 Research and Development 122
10.5.2.1 Pre-clinical Studies 122
10.5.2.2 Clinical Studies 122
10.5.2.2.1 Phase I 122
10.5.3 Product Development Activities 123
10.5.3.1 Collaboration Agreement 123
10.5.3.2 Technology 124
10.6 Ifenprodil: Algernon Pharmaceuticals 126
10.6.1 Product Description 126
10.6.2 Research and Development 126
10.6.2.1 Pre-clinical Studies 126
10.6.2.2 Clinical Studies 127
10.6.2.2.1 Planned Phase II 127
10.6.3 Product Development Activities 127
10.6.3.1 Recent Initiatives towards COVID-19 Pandemic 127
10.6.3.2 Manufacturing Agreement 128
10.6.3.3 IND Application 128
10.6.3.4 Contract Agreement 128
10.7 Remestemcel-L: Mesoblast 130
10.7.1 Product Description 130
10.7.2 Research and Development 130
10.7.2.1 Clinical Studies 130
10.7.2.1.1 Phase II/III 130
10.7.3 Product Development Activities 131
10.7.3.1 IND Application 131
10.7.3.2 Partnership 131
10.7.3.3 Licensing Agreement 131
10.8 TJM2: I-Mab Biopharma 133
10.8.1 Product Description 133
10.8.2 Research and Development 133
10.8.2.1 Clinical Studies 133
10.8.2.1.1 Phase I 133
10.8.3 Product Development Activities 133
10.8.3.1 IND Application 133
11. PRE-CLINICAL AND DISCOVERY STAGE PRODUCTS 135
11.1 Comparative Analysis 135
12. THERAPEUTIC ASSESSMENT (CLINICAL PRODUCTS) 137
12.1 Assessment by Stage and Product Type 137
12.2 Assessment by Stage and Product Type 138
12.3 Assessment by Route of Administration 139
12.4 Assessment by Stage and Route of Administration 140
12.5 Assessment by Molecule Type 141
12.6 Assessment by Stage and Molecule Type 142
13. EXECUTIVE SUMMARY 143
14. VACCINES UNDER DEVELOPMENT BY COMPANIES 145
14.1 Clinical Stage Vaccines 145
14.2 Ad5-nCoV: CanSino Biologics Inc. 146
14.2.1 Product Description 146
14.2.2 Research and Development 146
14.2.2.1 Pre-clinical Studies 146
14.2.2.2 Clinical Studies 146
14.2.2.2.1 Phase I 146
14.2.3 Product Development Activities 146
14.2.3.1 Technology 146
14.3 mRNA-1273: Moderna Inc. 148
14.3.1 Product Description 148
14.3.2 Research and Development 148
14.3.2.1 Clinical Studies 148
14.3.2.1.1 Phase I 148
14.3.3 Product Development Activities 149
14.3.3.1 Funding 149
14.4 INO-4800: Inovio Pharmaceuticals 151
14.4.1 Product Description 151
14.4.2 Research and Development 151
14.4.2.1 Pre-clinical Studies 151
14.4.2.2 Clinical Studies 151
14.4.2.2.1 Phase I 151
14.4.3 Product Development Activities 152
14.4.3.1 Collaboration 152
14.4.3.2 Funding 152
14.5 Non-Clinical Stage Vaccines 154
15. VACCINES UNDER DEVELOPMENT BY UNIVERSITIES 157
Table 2: SARS-CoV-2 Tests Commercially Available or in Development for the Diagnosis of COVID-19 31
Table 3: Summary of Chemotherapeutic Drugs under Clinical Trial for COVID-19 52
Table 4: Clinical Products under Development by Target 59
Table 5: Total Number of Products in COVID-19 61
Table 6: Late Stage Products (Phase III) 62
Table 7: Clinical Trial Description: ASC09+Ritonavir 63
Table 8: General Description: ASC09+Ritonavir 64
Table 9: Clinical Trial Description: CD24Fc 68
Table 10: General Description: CD24Fc 68
Table 11: Clinical Trial Description: Favipiravir 70
Table 12: General Description: Favipiravir 70
Table 13: Clinical Trial Description: Hydroxychloroquine 74
Table 14: General Description: Hydroxychloroquine 74
Table 15: Clinical Trial Description: Remdesivir 77
Table 16: General Description: Remdesivir 78
Table 17: Clinical Trial Description: Ruxolitinib 80
Table 18: General Description: Ruxolitinib 80
Table 19: Clinical Trial Description: Tocilizumab 83
Table 20: General Description: Tocilizumab 83
Table 21: Clinical Trial Description: Tradipitant 86
Table 22: General Description: Tradipitant 86
Table 23: Mid Stage Products (Phase II) 88
Table 24: Clinical Trial Description: APN-01 90
Table 25: General Description: APN-01 91
Table 26: Clinical Trial Description: Aviptadil 92
Table 27: General Description: Aviptadil 93
Table 28: Clinical Trial Description: BXT-10 96
Table 29: General Description: BXT-10 97
Table 30: Clinical Trial Description: Leronlimab 99
Table 31: General Description: Leronlimab 99
Table 32: Clinical Trial Description: Lopinavir+Ritonavir 101
Table 33: General Description: Lopinavir+Ritonavir 102
Table 34: Clinical Trial Description: Plitidepsin 104
Table 35: General Description: Plitidepsin 104
Table 36: Clinical Trial Description: Sarilumab 108
Table 37: General Description: Sarilumab 109
Table 38: Clinical Trial Description: SNG001 112
Table 39: General Description: SNG001 113
Table 40: Early Stage Products (Phase I and IND) 115
Table 41: Clinical Trial Description: AmnioBoost 117
Table 42: General Description: AmnioBoost 117
Table 43: Clinical Trial Description: Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir 118
Table 44: General Description: Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir 118
Table 45: Clinical Trial Description: Gimsilumab 121
Table 46: General Description: Gimsilumab 121
Table 47: Clinical Trial Description: REGN3048+REGN3051 123
Table 48: General Description: REGN3048+REGN3051 124
Table 49: Clinical Trial Description: Ifenprodil 127
Table 50: General Description: Ifenprodil 128
Table 51: Clinical Trial Description: Remestemcel-L 131
Table 52: General Description: Remestemcel-L 132
Table 53: General Description: TJM2 134
Table 54: Pre-clinical and Discovery Stage Products 135
Table 55: Assessment by Stage and Product Type 137
Table 56: Assessment by Stage and Product Type 138
Table 57: Assessment by Route of Administration 139
Table 58: Assessment by Stage and Route of Administration 140
Table 59: Assessment by Molecule Type 141
Table 60: Assessment by Stage and Molecule Type 142
Table 61: Clinical Stage Vaccines 145
Table 62: Clinical Trial Description: Ad5-nCoV 146
Table 63: General Description: Ad5-nCoV 147
Table 64: Clinical Trial Description: mRNA-1273 149
Table 65: General Description: mRNA-1273 149
Table 66: Clinical Trial Description: INO-4800 151
Table 67: General Description: INO-4800 152
Table 68: Non-clinical Stage Vaccines 154
Table 69: Vaccines Under Development By Universities 157
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
